Lonza expansion takes Extract Technology to Singapore
Extract Technology, of Huddersfield in the UK, was recently awarded a major contract from engineering contractors Bovis Lend Lease Pharmaceutical Pte Ltd in Singapore.
The company will supply the critical containment equipment in the dispensary and sampling areas of the new US$290m (€197m) biologics manufacturing plant being built by Swiss custom manufacturing firm Lonza.
Extract Technology had successfully installed equipment at Lonza’s existing US biopharmaceutical manufacturing plant in Portsmouth, New Hampshire, and the new Singapore site was initially designed to be a replica facility.
Extract will be supplying three dispensing booths, one sampling booth and two dispensing benches – an almost identical installation to that in New Hampshire, with all the equipment offering maximum protection to both the product and the operator through the precise control of airflow and the capture of micro-fine dust particles.
‘Apart from a few minor adjustments, we will be replicating the installation that has proved so successful in the US,’ said Mike Davies of Extract Technology. ‘The building is up now and we are shipping equipment out to Singapore in November for installation and commissioning early in 2008.’
The Singapore facility is Lonza’s second in the country and will be a large-scale commercial mammalian cell culture manufacturing plant.
